20216921 34557537.0

IRB Approved at the Protocol Level Jun 16, 2022

Exploring a path that may delay the development of Parkinson's disease symptoms

Learn about a Parkinson's disease study researching an investigational drug

About the Luma Study

The Luma Study is evaluating the safety and efficacy of a study drug, as compared to a placebo, to see if it may delay the progression of Parkinson's disease in people who are in the early stage of their condition.

How do I qualify for the study?

You may be eligible to participate if you:*

- Are 30 to 80 years old
- Were diagnosed with Parkinson's disease within the last 2 years and were at least 30 years old when you were diagnosed

*The study team will discuss with you the additional criteria required to participate.

Why take part?

If you qualify and decide to take part, you will receive:

- All study-related care and study drug at no charge
- Regular monitoring of your Parkinson's disease and overall health by physicians who specialize in Parkinson's disease
- Reimbursement for transportation and rideshare to attend study visits, as needed
- The opportunity to contribute to learning more about Parkinson's disease

Your safety is our highest priority while participating. If you have any questions or concerns at any point throughout the study, a study staff member is available. The study staff can also tell you about their COVID-19 safety protocols.

Your participation is voluntary, and you are free to withdraw at any time, for any reason. Your privacy will be maintained throughout the study.

For more information or to see if you qualify:

Ray James, RN, Site Coordinator 617-638-7745 rcjames@bu.edu





Copyright © 2022 Biogen Inc., Biogen-151296 Luma Study_Patient Flyer_US English_V1_25APR2022